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Abstract
Nipah virus (NiV) and Hendra virus (HeV) are the only paramyxoviruses requiring Biosafety Level
4 (BSL-4) containment. Thus, study of henipavirus entry at less than BSL-4 conditions necessitates
the use of cell-cell fusion or pseudotyped reporter virus assays. Yet, these surrogate assays may
not fully emulate the biological properties unique to the virus being studied. Thus, we developed a
henipaviral entry assay based on a β-lactamase-Nipah Matrix (βla-M) fusion protein. We first
codon-optimized the bacterial βla and the NiV-M genes to ensure efficient expression in mammalian
cells. The βla-M construct was able to bud and form virus-like particles (VLPs) that morphologically
resembled paramyxoviruses. βla-M efficiently incorporated both NiV and HeV fusion and
attachment glycoproteins. Entry of these VLPs was detected by cytosolic delivery of βla-M,
resulting in enzymatic and fluorescent conversion of the pre-loaded CCF2-AM substrate. Soluble
henipavirus receptors (ephrinB2) or antibodies against the F and/or G proteins blocked VLP entry.
Additionally, a Y105W mutation engineered into the catalytic site of βla increased the sensitivity of
our βla-M based infection assays by 2-fold. In toto, these methods will provide a more biologically
relevant assay for studying henipavirus entry at less than BSL-4 conditions.
Background
The henipaviruses, Nipah (NiV) and Hendra (HeV), are
emerging zoonoses; the former caused multiple outbreaks
of fatal encephalitis in Malaysia, Bangladesh, and India
with mortalities ranging from 4070% while the latter pro-
duced respiratory syndromes among thoroughbred horses
in Australia whilst also being implicated in the death of a
horse handler [1-4]. These two paramyxoviruses, both
designated Category C priority pathogens by the NIAID
Biodefense Research Agenda, require strict Biosafety Level
4 (BSL-4) containment due to their extreme pathogenic-
ity, unverified mode(s) of transmission, and lack of pre-
or post-exposure treatments[4].
BSL-4 containment limits the opportunities for thorough
analysis of live henipavirus entry characteristics. Surrogate
assays to study henipavirus entry at less than BSL-4 condi-
tions exist, such as cell-cell fusion or VSV-based NiV-enve-
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used to probe envelope receptor interactions and charac-
terize the determinants of fusion with regards to both the
fusion (F) and attachment (G) envelope glycoproteins [5-
10]. However, cell-cell fusion lacks the geometric and
kinetic constraints found in virus-cell fusion while pseu-
dotyped VSV particles physically resemble Rhabdoviridae
rather than the pleomorphic Paramyxoviridae. Therefore,
neither assay may fully recapitulate the biological proper-
ties of native envelope structures of live henipaviruses.
Moreover, pseudotype reporter virus assays depend on
efficient transcription and translation of a reporter gene
after virus entry. Thus, earlier steps in viral entry, such as
matrix uncoating, may also not be resolved by either of
these assays.
Many viruses form virus-like particles (VLPs) via expres-
sion of their matrix alone (e.g. Sendai, HPIV-1, Ebola,
HIV, Rabies) or only in combination with envelope pro-
teins (e.g. Simian Virus 5, Measles) [11-19]. Paramyxovi-
ral matrix proteins direct budding of virions from the
surface of infected cells and interact with the endodomain
of envelope proteins, ultimately assisting in viral assem-
bly[11,20]. Specifically, NiV matrix (NiV-M) alone, or in
combination with its fusion protein (NiV-F) and receptor-
binding protein (NiV-G), buds and forms VLPs effi-
ciently[21,22]. Additionally, matrix may function to
recruit the nucleoprotein-encased genome to the budding
site[15,23]. Paramyxoviral matrix proteins perform essen-
tial roles in viral release/budding and presumably rely on
late domains[20,24] for these functions; although typical
late domain motifs have not been found in certain para-
myxoviral M proteins[25]. Thus, NiV matrix-based VLPs
will likely better reflect the biological properties of their
live-virus counterparts in entry assays. Here, we developed
a VLP-based assay that can be used for analyses of henipa-
viral entry characteristics under BSL-2 conditions. This
VLP assay is based on a β-lactamase-Nipah Matrix (βla-M)
fusion reporter protein.
β-lactamase (βla) is a commonly used reporter protein
whose reporter activity depends on its ability to cleave β-
lactam ring-containing fluorescent or colorimetric sub-
strates. For our purposes, CCF2-AM proved useful as a
cell-permeant fluorescent substrate engineered to exhibit
a shift from green to blue fluorescence upon βla cleavage
[26-28]. CCF2-AM cell loading is nearly 100% efficient,
practically irreversible (cytoplasmic esterases prevent
CCF2 from diffusing out of the cells), and permits loading
of a variety of cell types including primary neuron or
microvascular endothelial cells, the main targets of NiV
infection. Thus, virus-cell fusion of envelope bearing βla-
M VLPs should deliver βla-M to the cytosol leading to flu-
orescent conversion of the pre-loaded CCF2 substrate. The
shift from green to blue fluorescence can then be quanti-
fied by flow cytometry or quantitative microscopy.
Genetic optimization of both the expression and the
intrinsic enzymatic efficiency of the βla-M reporter
allowed for sensitive, specific and relatively high-through-
put analyses of henipavirus entry in the absence of vac-
cinia augmentation. Our results suggest that this strategy
may be generalized to other viruses where matrix is the
primary determinant of budding and virion morphology.
Results
Synthesis of the β-lactamase-Nipah Matrix (βla-M) fusion 
construct and its incorporation into virus-like particles 
(VLPs)
NiV-M is a small, basic and moderately hydrophobic 352
amino-acid protein and one of the most abundant pro-
teins within the virion. Therefore, we chose to fuse a
reporter protein to NiV-M in a manner that does not inter-
fere with its ability to form VLPs. Published data shows
that the C-terminal end of many matrix proteins regulates
complex functions involved in budding and viral assem-
bly[20,25,29-35]; thus, we decided to fuse the β-lactamase
gene (βla) onto the N-terminus of NiV-M. Examination of
the codon-usage of wild-type βla and wild-type NiV-M
revealed a skewing towards the use of rare mammalian
codons (Fig. 1a). Therefore, we codon-optimized both βla
and NiV-M to produce a fully codon-optimized βla-M
gene for efficient expression in mammalian cells (see
Materials and Methods).
Codon-optimized NiV-M and βla-M were equivalently
expressed in transfected 293T cells (Fig. 1b). Notably,
fusion of codon-optimized βla to wild-type NiV-M (NiV-
MWT) resulted in almost undetectable expression of βla-M
under similar transfection conditions (data not shown).
To verify incorporation of NiV-M and βla-M into VLPs, we
transfected 293T cells with codon-optimized NiV-M or
βla-M along with the corresponding codon-optimized
NiV-F and NiV-G envelope glycoproteins. After isolating
VLPs from the transfected cell supernatants, we verified
the presence of NiV-M or βla-M within the lysed VLPs by
immunoblotting with NiV-M-specific antibodies (Fig. 1c).
Only M-containing VLPs with both NiV-F and NiV-G on
their surface will be infectious in our entry assays and
these data suggest that fusion of βla to NiV-M did not per-
turb the ability of NiV-M to form VLPs or incorporate cog-
nate viral envelope glycoproteins. Coexpression of
nucleocapsid (N) along with NiV-M or βla-M did not alter
the overall production of M-containing VLPs (data not
shown), consistent with findings from other groups[21].
βla-M+NiV-F/G VLPs morphologically, biochemically, and 
biologically mimic live NiV
NiV-M will bud and form VLPs in the presence or absence
of co-transfected NiV-F and NiV-G[21,22]. Thus, we also
determined how well βla-M would bud and form VLPs in
the presence or absence of NiV-F and NiV-G. Fig. 2a shows
that the βla-M construct also budded and formed VLPs inPage 2 of 11
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Synthesis of the β-lactamase-matrix (βla-M) fusion construct and its incorporation into virus-like particles (VLPs)Figure 1
Synthesis of the β-lactamase-matrix (βla-M) fusion construct and its incorporation into virus-like particles 
(VLPs). a) Codon usage comparisons between wild-type NiV-M (henipavirus), βla (bacteria) and average Homo sapiens genes. 
For clarity, only representative amino acids with significant differences in codon usage frequencies between Homo sapiens and 
NiV-M or βla genes are shown. Note the skewing towards more rarely used mammalian codons. Overall, codon usage for 
amino acids not shown cumulatively demonstrate a pattern of rare mammalian codon usage (see Additional file 1). b) Cell 
lysates from transfected 293T cells were blotted for protein expression using anti-M antibodies. c) VLPs collected from NiV-
M+NiV-F/G or βla-M+NiV-F/G transfected 293T cell supernatants were purified as described in the materials and methods. 
VLPs were lysed and blotted for protein incorporation using anti-NiV-M antibodies along with anti-HA (NiV-G) antibodies to 
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βla-M+NiV-F/G VLPs morphologically, biochemically, and biologically mimic live NiVFigure 2
βla-M+NiV-F/G VLPs morphologically, biochemically, and biologically mimic live NiV. a) VLPs produced in the 
presence (+) or absence (-) of envelope proteins were lysed and blotted for protein incorporation using anti-HA (NiV-G), anti-
AU1 (NiV-F), or anti-NiV-M antibodies. b) Purified particles were analyzed under electron microscopy as described in materi-
als and methods at 72,000× magnification. 1(z) = βla-M+NiV-F/G VLPs, 2 = NiV-M+F/G VLPs, 3 = pseudotyped VSV+NiV-F/G. 
Scale bars represent 100 nm. c) Vero cells were infected with NiV-F/G VLPs containing the βla-M fusion protein. Soluble 
ephrinB2-Fc and ephrinB1-Fc were added to a final concentration of 75 nM. Anti-NiV-F (834), anti-NiV-G (806), and pre-
immune sera were added to a final concentration of 5 μg/ml. Infected cells (% blue positive) were quantified using flow cytom-
etry with untreated entry (NoTx) normalized as 100%. Data shown as an average of triplicates from three individual experi-
ments ± SEM. d) Fluorescence microscopy was performed on representative corresponding wells from (c) at 20× 
magnification using a beta-lactamase dual-wavelength filter (Chroma Technologies, Santa Fe Springs, CA).
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similar to what has been shown for NiV-M[21,22].
Next, we characterized the morphology of the VLPs by
imaging the βla-M VLPs via electron microscopy. Fig. 2b
shows that βla-M VLPs closely resembled the morphology
and size of standard NiV-M VLPs, and both exhibited the
standard pleomorphic shape representative of Paramyxo-
viridae, ranging in size from 50 nm to 800 nm[36]. The
images also resolved the presence of viral "spikes" pro-
truding from the particles; these represent the viral enve-
lope glycoproteins of NiV on the surface of the particle,
confirming their incorporation into the VLPs. Tellingly,
pseudotyped VSV+NiV-F/G particles resembled classical
bullet-shaped Rhabdoviridae particles (Fig. 2b). This fur-
ther underscores potential biological differences that may
occur when using NiV-M based VLPs versus VSV pseudo-
types.
Fig. 2c shows the specificity and sensitivity of our βla-M
VLP entry assay via flow cytometry analyses. Entry of βla-
M+NiV-F/G VLPs into Vero cells produced signals with a
25-fold dynamic range over βla-M VLPs lacking NiV viral
envelope proteins (Fig. 2c). For simplicity, we will refer to
successful entry of βla-M+NiV-F/G VLPs into susceptible
cells as "infection" and to βla-M VLPs lacking NiV viral
envelope proteins as "bald" VLPs. To verify receptor-spe-
cificity within our assay, we infected in the presence of sol-
uble NiV receptor, ephrinB2-Fc, which successfully
inhibited infection while a non-receptor homologue,
ephrinB1-Fc, did not (Fig. 2c). In addition, anti-NiV-F and
anti-NiV-G polyclonal antibodies[10,37], but not the pre-
immune sera, also inhibited infection (Fig. 2c) emphasiz-
ing that the βla-M+NiV-F/G VLPs emulate the known roles
of F and G in mediating paramyxoviral entry. Green to
blue color shifts in CCF2-loaded cells were also confirmed
visually (Fig. 2d) before flow analyses. Collectively, these
data establish that the βla-M VLPs physically and bio-
chemically resemble NiV while the infection reflects the
receptor and envelope specificity of live Nipah viruses.
βla-M+NiV-F/G VLPs infect biologically relevant cells in a 
receptor-dependent manner
To further illustrate the biological relevance of our βla-M
VLP entry assay, we used βla-M VLPs to infect primary cell
targets of natural NiV infection. The formation of giant-
multinucleated syncytia in human microvascular
endothelial cells (HMVECs) is a pathogenic hallmark of
NiV infection[38]. Thus, we used βla-M VLPs to infect
HMVECs preloaded with CCF2-AM (Fig. 3a and Fig. 3b).
Interestingly, we observed a significant improvement in
signal to noise ratio compared to the read-out from Vero
cell infections. Again, the cognate soluble NiV receptor,
ephrinB2-Fc, but not ephrinB1-Fc, inhibited infection of
HMVECs, underscoring the receptor specificity of NiV VLP
infection in these primary cells (Fig. 3a and Fig. 3b).
Finally, to demonstrate that these infections took place
within the linear range of our assay, we serially diluted the
βla-M VLPs as indicated and found the amounts used to
infect HMVECs were within the linear range (Fig. 3c).
Hendra virus (HeV) envelope proteins package efficiently 
onto βla-M(NiV) and produce infectious VLPs
Molecular and immunological data indicate that NiV and
HeV are closely related viruses that can be appropriately
clustered into a new henipavirus genus. Indeed, NiV and
HeV F and G proteins can functionally cross-complement
each other[5,39]. However, it remains unknown whether
NiV-M can complement the function of HeV-M to pro-
duce infectious HeV envelope bearing VLPs. While rhab-
doviral matrices can functionally accommodate many
heterologous envelope proteins, it is less clear whether
paramyxoviral matrix proteins can incorporate heterolo-
gous envelope proteins in a functional manner. Fig. 4a
shows that our βla-M(NiV) construct allowed efficient for-
mation of HeV-enveloped VLPs at levels equivalent to
NiV-enveloped VLPs (Fig. 4a and 2a). Infecting HMVECs
with βla-M(NiV)+HeV-F/G VLPs produced a similar
dynamic range to that of βla-M(NiV)+NiV-F/G particles
(data not shown). βla-M(NiV)+HeV-F/G VLP infection
was similarly envelope dependent as an anti-HeV-F spe-
cific monoclonal antibody inhibited infection while an
anti-NiV-F specific monoclonal[37] and non-specific
monoclonal antibodies had little to no effect (Fig. 4b).
βla-M VLPs enveloped with the NiV-GE505A mutant 
recapitulate differential receptor usage
NiV and HeV exhibit analogous tropisms and both utilize
ephrinB2 and ephrinB3 for cellular entry; although how
well ephrinB2 or ephrinB3 allows for entry into various
primary cell targets of henipavirus infections remains to
be defined[9,40]. However, both NiV and HeV utilize
ephrinB2 with much greater efficiency than
ephrinB3[9,40]. Interestingly, a point mutation (E505A)
within the globular domain of NiV-G abrogates efficient
B3-dependent entry while leaving B2-dependent entry
unaffected[39]. We previously argued that differential
ephrinB2 versus B3 usage may have direct pathogenic rel-
evance as only ephrinB3 is expressed in the brain-
stem[39,41], the site of neuronal dysfunction ultimately
causing death from encephalitis after NiV infection[42].
Thus, to fully contextualize this previously reported phe-
notype, we sought to determine if the differential receptor
usage of the NiV-GE505A mutant is fully recapitulated usingβla-M VLPs. Indeed, incorporation of an NiV-GE505A enve-
lope mutant along with NiV-F onto βla-M resulted in VLPs
defective in their ability to gain entry into CHO-B3 cells,
but not CHO-B2 cells (Fig. 5a)[39]. Fig. 5b shows that
both the NiV-GE505A mutant and NiV-GWT (both along
with NiV-F) are equivalently incorporated into VLPs and,Page 5 of 11
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due to different levels of envelope incorporation.
A Y105W mutation within the active site of βla increases 
cleavage efficiency resulting in a more sensitive entry assay
To further increase the sensitivity of our βla-M based assay
for future high-throughput tasks, we sought to improve
the catalytic activity of βla. Active site mutations have
been shown to increase the substrate cleavage efficiency of
βla for certain β-lactam containing antibiotics in an
enzyme subtype and substrate specific manner [43-46].
Thus, we searched the literature for active site mutations
that increase the catalytic activity of the βla (TEM1 strain)
for the substrate cefazolin, the most closely related β-
lactam to CCF2-AM. A tyrosine to tryptophan (Y105W)
mutation within the active site of the TEM1-βla increases
the catalytic activity (Kcat/Km) for cefazolin by 1.5-
fold[46]. Therefore, we engineered this Y105W mutation
into βla-M (βlaY105W-M) in order to increase the assay sen-
sitivity and make the system more amenable to high-
throughput tasks. Indeed, βlaY105W-M increased the signal
to noise ratio obtained in our VLP entry assay 1.8-fold
(Fig. 6a) while overall VLP production levels remained
similar (Fig. 6b). Thus, βlaY105W-M appears to have
increased the sensitivity of our VLP entry assay on a per
virion basis.
βla-M+NiV-F/G VLPs infect a biologically relevant cell line in a receptor-dependent mannerFigure 3
βla-M+NiV-F/G VLPs infect a biologically relevant cell line in a receptor-dependent manner. a) HMVECs were 
infected with βla-M+NiV-F/G or βla-M-only VLPs and quantified via flow cytometry. Soluble ephrinB2-Fc or ephrinB1-Fc was 
added at a final concentration of 75 nM. Infected cells (% blue positive) were quantified using flow cytometry with untreated 
entry (NoTx) normalized as 100%. Data shown as an average of triplicates from three individual experiments ± SEM. b) Repre-
sentative flow cytometry plots of the data from (3a). c) βla-M+NiV-F/G VLPs from (a) were diluted in increments and used to 
infect HMVECs as previously described. Infected cells (% blue positive) were quantified using flow cytometry. Data shown as 
singlets from a single representative experiment.
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Many viral entry studies on highly pathogenic agents have
relied on cell-cell fusion and envelope pseudotyped
reporter assays which have permitted detailed analyses of
their entry characteristics without high-level biosafety
containment. Yet, these surrogate assays may not fully
emulate the biological properties unique to the virus
being studied. Cell-cell fusion assays do not mimic virus-
cell fusion kinetics and are not constrained by the geome-
try of virus-cell fusion, and envelope pseudotyped viral
systems reflect the virion morphology of the backbone
virus rather than the parental virus from which the enve-
lopes are derived. Such differences may confound accurate
dissection of the entry pathway under study. Pseudotyped
reporter virus assays also require efficient replication and
transcription of the reporter gene in the cell type used, and
thus, post-entry factors may influence the efficiency of
reporter gene expression. For BSL-4 containment viruses
like NiV and HeV, the problems are compounded by the
limited availability of resources to confirm the results of
surrogate assays in live henipaviruses. Thus, we sought to
develop a system that more faithfully replicates the native
henipavirus entry process. This will allow for a more
detailed and biologically relevant analysis of early entry
events and will facilitate the development of high-
Hendra virus (HeV) envelope proteins package efficiently onto βla-M(NiV) and produce infectious VLPsFigure 4
Hendra virus (HeV) envelope proteins package effi-
ciently onto βla-M(NiV) and produce infectious VLPs. 
a) VLPs collected from βla-M(NiV)+ HeV-F/G or βla-
M(NiV)-only transfected 293T supernatant were purified as 
described in the materials and methods. VLPs were lysed and 
blotted for proteins using anti-HA (HeV-G), anti-AU1 (HeV-
F), or anti-NiV-M antibodies. b) HMVECs were infected by 
βla-M(NiV)+ HeV-F/G VLPs in the presence of anti-HeV-F 
specific (mAb 36) or anti-NiV-F specific (mAb 66)[37] mono-
clonal antibodies with non-specific monoclonal antibodies as 
a negative control to a final concentration of 20 μg/ml. 
Infected cells (% blue positive) were quantified using flow 
cytometry with untreated (NoTx) entry normalized as 100%. 








βla-M VLPs enveloped with the NiV-GE505A mutant recapitu-late differential receptor usageFigure 5βla-M VLPs enveloped with the NiV-GE505A mutant 
recapitulate differential receptor usage. a) Enveloped 
βla-M VLPs incorporating an E505A mutation in NiV-G were 
used to infect CHO-B2 or CHO-B3 cells stably expressing 
only ephrin-B2 or ephrin-B3, respectively. Infected cells (% 
blue positive) were quantified using flow cytometry with 
ephrin-B2 mediated entry normalized as 100%. Data shown 
as an average of triplicates from three individual experiments 
± SEM. b) VLPs from (5a) were lysed and blotted for protein 
incorporation using anti-HA (NiV-G/NiV-GE505A), anti-AU1 







A single amino acid (Y105W) mutation within the active site of βla increases leavage efficiency resulting a more sensi-tive entry as ayFigure 6
A single amino acid (Y105W) mutation within the 
active site of βla increases cleavage efficiency result-
ing in a more sensitive entry assay. a) Vero cells were 
infected with βla-M, βlaY105W-M, βla-M+NiV-F/G and βlaY105W-M+NiV-F/G VLPs. Infected cells (% blue positive) 
were quantified using flow cytometry with βla-M+NiV-F/G 
infection normalized as 100%. Data shown as an average of 
triplicates from one representative experiment ± SD. b) 
VLPs were lysed and blotted for protein incorporation using 
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entry processes.
VLPs can be produced via expression of viral matrices
alone or in combination with their respective envelope
proteins [11-19]. Paramyxoviral matrix proteins, abun-
dant within the virion, seemingly act as the 'bandleader'
by coordinating several events within the viral life cycle:
envelope protein localization, assembly and budding,
nucleocapsid or genome recruitment, and particle disas-
sembly or uncoating[11,47]. Thus, these VLPs more faith-
fully mimic their live virus counterparts and permit a
more biologically relevant analysis of entry and uncoating
kinetics. Despite these many functionalities, none appear
to be significantly disrupted by fusing large reporter pro-
teins like GFP, Renilla luciferase, or βla to the N-terminus
of NiV-M[22] (Fig. 2 and unpublished observations).
Thus, we sought to exploit this property by fusing the β-
lactamase enzyme to the N-terminus of NiV-M in an effort
to create a sensitive and specific viral entry assay.
Several viral entry assays have been developed that rely on
cytosolic delivery, or intravirion detection, of a virion
associated reporter fusion protein. For example, entry
assays using vpr-βla for HIV and βla-matrix for Ebola have
been described[48,49], yet the published assays would
appear to be less sensitive than our current system[48,50].
In the process of making our βla-M reporter, we discov-
ered that both the NiV-M and the βla genes tended to use
rare mammalian codons (Fig. 1a and see Additional file
1). Indeed, our βla-M fusion construct yielded significant
protein expression only when both genes were fully
codon-optimized (Fig. 1bc and data not shown). This
could explain why NiV-M is poorly expressed in the
absence of vaccinia augmentation[21] and why βla based
real-time fusion assays are more sensitive and robust
when using codon-optimized βla[37]. Codon-optimiza-
tion alone likely results in the larger dynamic range and
greater sensitivity of our βla-M based assays.
Our βla-M VLPs adopt the pleomorphic morphology of
paramyxoviruses and incorporate henipaviral envelopes
in a manner indistinguishable from wild-type NiV-M
VLPs. NiV and HeV envelope bearing βla-M VLPs recapit-
ulate their biological phenotypes in terms of receptor
usage and the requirements for F and G in the paramyxo-
viral entry process (Figs. 2, 3, 4 and 5). Importantly, βla-
M VLPs can be used to study early entry events in primary
cell targets of henipavirus infections, such as HMVECS,
without potentially confounding factors like virus replica-
tion mediated cytotoxicity or other post-entry restriction
factors. Significantly, the βla-M VLPs can also assay virus
uncoating (i.e. virus-cell content mixing) via detection of
viral matrix protein exposure to the cellular cytoplasm.
While it is clear that Rhabdoviridae can functionally
accommodate many different heterologous envelopes
[51-54], it is less clear whether paramyxoviral matrix pro-
teins have the ability to functionally cross-complement
other members of the family. We demonstrated here that
βla-M(NiV) was able to complement and package the HeV
envelope proteins, emphasizing the relatedness between
these two viruses. Our results open the possibility that
other paramyxoviral envelope proteins can functionally
cross-complement onto βla-M(NiV), or their own respec-
tive βla-matrix fusion constructs, thereby providing a
more efficient and high-throughput assay to study para-
myxoviral entry. Arguably, short of reverse genetics to
study matrix and envelope mutants in the context of par-
ent paramyxoviruses, this βla-M VLP assay better reflects
the native biology of paramyxoviral entry than other sur-
rogate assays. To further improve the sensitivity of this
assay for high-throughput applications, we exploited the
vast literature on β-lactam structure-function studies and
engineered a Y105W mutation into the active site of βla
known to increase the cleavage efficiency of the enzyme
[43-46] (Fig. 6).
In summary, we have developed a codon-optimized cata-
lytically improved βla-M based VLP system that can be
used for henipaviral entry studies. The flexibility of using
either colorimetric or cell permeant fluorimetric sub-
strates in the same βla-M VLP system allows for efficient,
quantitative, and more high throughput analyses of heni-
pavirus fusion and entry characteristics that more closely
reflect those of authentic viral particles. Whether βla-M
can be complemented with other paramyxoviral enve-
lopes remains to be determined, but such studies will pro-
vide information into the specificity of matrix-envelope
interactions. Lastly, our results imply that such a codon-
optimized, catalytically improved βla-M based entry sys-
tem may be adapted to other viruses that possess a matrix
protein primarily responsible for virion morphology and
budding characteristics.
Materials and methods
Codon optimization and expression plasmids
The codon-optimized NiV-F or HeV-F and NiV-G or HeV-
G gene products were tagged at their C-termini with an
AU1 or hemagglutinin (HA) tag, respectively, as previ-
ously described[37,39]. NiV-MWT was synthesized by Ori-
gene (Rockville, MD). GeneArt (Regensburg, Germany)
performed mammalian codon-optimization of the NiV-M
gene (M) product according to in-house proprietary soft-
ware that addresses codon usage, elimination of cryptic
splicing sites, as well as the stability of DNA/RNA second-
ary structures. NiV-M was subcloned into pcDNA3.1 (Inv-
itrogen, Carlsbad, CA) between HindIII and XhoI
restriction enzyme sites. The sequence of the codon-opti-
mized NiV-M has been deposited into GenBank (Acces-Page 8 of 11
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optimized the βla gene, which was then subcloned into a
pVAX1 (Invitrogen) expression vector between the KpnI
and XhoI restriction enzyme sites. The sequence of the
mammalian codon-optimized βla has been deposited
into GenBank (Accession: EU744548). The βla gene was
fused upstream of the NiV-M gene by overlap PCR and
subsequently cloned into pcDNA3.1 via flanking KpnI
and XhoI restriction enzyme sites with a NotI restriction
enzyme site engineered in between the two genes. A single
Y105W amino acid mutation within the βla active site was
introduced using site-directed mutagenesis with Quik-
Change™ (Stratagene, La Jolla, CA). βlaY105W was then
cloned into pcDNA3.1 via flanking KpnI and NotI restric-
tion enzyme sites. All gene products were confirmed by
sequencing.
Antibody Production
Production protocols to provide polyclonal antibodies
(Rb. #2702, terminal bleed) via immunized rabbits (using
a 20-mer antigenic peptide sequence corresponding to
amino acids 2949 of NiV-M) were generated by the Pinna-
cle Antibody Program (21st Century Biochemicals, Marl-
boro, MA). Monoclonal anti-HeV specific antibodies were
produced by expressing HeV-F, HeV-G, and NiV-M in rab-
bits then isolating and screening specific anti-HeV lym-
phocytes from rabbit spleens as previously described for
anti-NiV-F specific monoclonal antibodies[37].
Cell culture
293T cells were grown in Dulbecco's modified Eagle's
medium (Invitrogen) containing 10% fetal bovine serum
(FBS) (Omega Scientific, Tarzana, CA). Vero cells were
grown in minimal essential medium alpha (Invitrogen),
containing 10% FBS. CHO stable cell lines expressing
ephrinB2 or ephrinB3 were derived and maintained as
previously described[9]. HMVECs were grown in EGM-2
media supplemented with the MV Bullet Kit (Cambrex,
Baltimore, MD). 293T and Vero cells were purchased from
the ATCC. HMVEC cells were a kind gift from R. Shao.
Production of βla-M(NiV) VLPs
βla-M expression plasmids (25 μg) and either NiV-F and
G or HeV-F and G (10 μg each) or pcDNA3 (20 μg) expres-
sion plasmids were transfected into 10 cm dishes of 293T
cells using Lipofectamine 2000 (Invitrogen). At 24 h post-
transfection, supernatants were collected and clarified
before pelleting the VLPs at 110,000 g through a 20%
sucrose (in PBS) cushion followed by resuspension in PBS
(Invitrogen) containing 5% sucrose.
Immunoblotting of VLP proteins
βla-M VLP-containing supernatants were lysed and sepa-
rated by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and subsequently detected by
immunoblotting using rabbit-anti-NiV-matrix (to detect
all NiV-M proteins), goat-anti-HA-HRP (to detect all G
proteins) (Novus Biologicals, Littleton, CO), or mouse-
anti-AU1 (to detect all F proteins) (Covance, Princeton,
NJ) antibodies. Primary and secondary antibodies were
used at 1:1,000 and 1:80,000 dilutions, respectively, or
1:10,000 for anti-HA-HRP followed by FEMTO (Pierce,
Rockford, IL) detection. Due to the similar molecular
weights of βla-M (~70 kDa) and NiV-G (~67 kDa), mem-
branes were probed for NiV-M, NiV-F or HeV-F, and NiV-
G or HeV-G individually.
Electron microscopy
200-mesh Formvar carbon-coated copper grids (Electron
Microscopy Sciences, Hatfield, PA) were floated on drops
of the NiV VLP suspensions at room temperature, then
blotted and stained with 1% aqueous uranyl acetate (UA)
for NiV VLPs and 2% aqueous solution of phosphotung-
stic acid (PTA) for VSV particles. Electron microscopy
studies were performed on a Philips 201 electron micro-
scope at 70 kV.
Quantification of βla-M VLP entry via FACS Aria
Cells were plated into 24-well plates at a confluency of
75% and spinoculated (2,000 g) with βla-M VLPs for 2 h
at 37°C. Although not required for efficient VLP entry,
spinoculation has been shown to significantly improve
the entry efficiency of several viruses (e.g. HIV, HHV-6,
CMV) into target cells[55,56] and, indeed, improved the
signal to noise ratio within our assay (data not shown).
Target cells were then stained with CCF2-AM substrate
according to the manufacturer recommendations (Pan-
vera, Madison, WI). The enzymatic reaction was allowed
to take place at 25°C for 18 h. The cells were then washed,
resuspended in FACS-buffer (2% FBS in PBS) and fixed
with 2% paraformaldehyde. Cells were then acquired
using FACS-Diva software on a FACS Aria machine (BD
Biosciences, San Diego, CA) with excitation at 407 nm
and emission at 520 nm and 447 nm. Samples were ana-
lyzed using FACS Convert and FCS Express v3 (De Novo
Software, Los Angeles, CA). Soluble ephrinB1-Fc and
ephrinB2-Fc fusion proteins were purchased from R&D
Systems (Minneapolis, MN). Data were analyzed by
GraphPad™ Prism Software (San Diego, CA) and repre-
sented as percentage infection (% blue positive cells).
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